Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
Cohort Analysis
85%
Overall Survival
57%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
45%
Non-Hodgkin Lymphoma
42%
Malignant Neoplasm
40%
Hazard Ratio
34%
COVID-19
33%
Diseases
31%
Acute Myeloid Leukemia
28%
Infection
27%
CHOP
27%
Population
23%
Lifespan
22%
Follicular Lymphoma
22%
Severe Acute Respiratory Syndrome Coronavirus 2
22%
Oncology
20%
Hodgkin's Lymphoma
19%
Clinical Trial
18%
Burkitt's Lymphoma
18%
Second Cancer
18%
Retrospective Cohort Study
18%
High Dose Chemotherapy
18%
Neonates
18%
Phototherapy
18%
Bilirubin
18%
Hematological Cancer
18%
Progression Free Survival
17%
Mortality
16%
Event Free Survival
15%
Rituximab
15%
Drug Megadose
15%
Symptom
15%
International Prognostic Index
14%
Psychoactive Drug
14%
Myelodysplastic Syndrome
13%
Diagnosis
13%
Personalized Medicine
12%
Classical Hodgkin Lymphoma
12%
Cardiovascular Disease
11%
Patient with Non-Hodgkins Lymphoma
11%
Stem Cell Transplant
10%
Bleomycin
10%
Doxorubicin
10%
Assisted Reproductive Technology
10%
Aggressive Lymphoma
10%
Socioeconomic Status
10%
Attributable Risk
10%
Mental Health
10%
Childbirth
10%
Pharmacology, Toxicology and Pharmaceutical Science
Diffuse Large B Cell Lymphoma
69%
Cohort Study
68%
Overall Survival
60%
Malignant Neoplasm
53%
Acute Myeloid Leukemia
46%
Remission
28%
Nonhodgkin Lymphoma
27%
Progression Free Survival
23%
Psychotropic Agent
23%
Chemotherapy
22%
Follicular Lymphoma
22%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
22%
Myelodysplastic Syndrome
20%
Clinical Trial
18%
Second Cancer
18%
Infection
18%
High Dose Chemotherapy
18%
Case-Control Study
18%
Myeloproliferative Neoplasm
18%
Disease
14%
Rituximab
13%
Large Cell Lymphoma
13%
Methotrexate
12%
Event Free Survival
11%
SARS Coronavirus
10%
Comorbidity
10%
Chimeric Antigen Receptor
10%
Burkitt's Lymphoma
10%
Patient Registry
9%
Life Expectancy
9%
Alzheimer's Disease
9%
Hodgkin Disease
9%
Bendamustine
9%
Alendronic Acid
9%
Primary Central Nervous System Lymphoma
9%
Bilirubin
9%
Obesity
9%
Survival Prediction
9%
Peripheral T Cell Lymphoma
9%
Chemokine Receptor CXCR4 Antagonist
9%
Prednisolone
9%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
9%
B Cell Lymphoma
9%
Hemodialysis
9%
Cardiovascular Disease
9%
Metformin
9%
Classical Hodgkin Lymphoma
9%
Solid Malignant Neoplasm
8%
Multiple Myeloma
7%
Glucocorticoid
6%
Keyphrases
National Cohort Study
36%
Lymphoma
29%
Lymphoma Patients
26%
High Risk
18%
Reproduction Pattern
18%
Denmark
18%
Second Primary Malignancy
18%
Cure Model
18%
Background Population
18%
Indolent Lymphoma
13%
Danish Population
10%
Population-based Study
10%
Adult Patients
10%
Hodgkin Lymphoma
10%
Cumulative Risk
10%
Acute Myeloid Leukemia
10%
Statistical Cure
9%
Plerixafor
9%
Sweden
9%
CXCR4 Antagonist
9%
High-dose Methotrexate (HD-MTX)
9%
Overall Survival
9%
Aggressive B-cell Lymphoma
9%
Matched Cohort Study
9%
Population-based Retrospective Cohort Study
9%
Multiplexed Proteomics
9%
Predictors of Infection
9%
Survival Prediction Model
9%
Work Disability
9%
Turquoise
9%
Light-emitting Diode (LED) Lamps
9%
Blue Light-emitting Diodes
9%
Molecular Classification
9%
Return to Work
9%
Pandemic Waves
9%
Autologous Hematopoietic Stem Cell Transplantation
9%
Bone Mineral Density
9%
Loss of Life Expectancy
9%
CNS Prophylaxis
9%
High-dose Chemotherapy
9%
Childbirth
9%
Temporal Change
9%
Swedish Population
9%
Flexible Parametric Model
9%
Lifetime Function
9%
Osteoporosis
9%
Vertebral Bone Quality
9%
Population-based
9%
Norway
9%
Bendamustine
9%